Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The ...

Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $456 from $476 and keeps an Equal ...